MARKET

JAGX

JAGX

Jaguar Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.410
+0.040
+1.69%
Pre Market: 2.300 -0.11 -4.56% 08:06 09/20 EDT
OPEN
2.360
PREV CLOSE
2.370
HIGH
2.410
LOW
2.300
VOLUME
621
TURNOVER
--
52 WEEK HIGH
13.41
52 WEEK LOW
0.5550
MARKET CAP
112.02M
P/E (TTM)
-1.4414
1D
5D
1M
3M
1Y
5Y
REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
Click to register for webcast
ACCESSWIRE · 3d ago
Jaguar Health Says European Medicines Agency Accepts for Review Its Orphan Drug Designation Application for Crofelemer
MT Newswires · 5d ago
Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
Participating investors include Jaguar CEO and CFO, Dragon SPAC S. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.
ACCESSWIRE · 5d ago
Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization of crofelemer prescription product for chemotherapy-indu...
ACCESSWIRE · 09/09 12:30
72 Biggest Movers From Yesterday
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.
Benzinga · 09/08 08:57
Cassava Sciences, NRx Pharmaceuticals, Innate Pharma among major healthcare premarket losers' pack
Jaguar Health (NASDAQ:JAGX) -21% slumps 10% on 1-for-3 reverse stock split announcement. Forward Pharma (NASDAQ:FWP) -17% after Technical Board of Appeal of the European Patent Office has dismissed Forward’s appeal of the previous
Seekingalpha · 09/07 12:22
Jaguar Health Stock Is Trading Lower In Reaction To Reverse Stock Split
Benzinga · 09/07 10:25
Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split, To Begin Trading On Split-Adjusted Basis On Sept. 8, 2021
Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders Shares of Jaguar common stock to begin trading on split-adjusted basis on September 8, 2021 Jaguar
Benzinga · 09/03 20:16
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAGX. Analyze the recent business situations of Jaguar Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JAGX stock price target is 13.50 with a high estimate of 15.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 7.40M
% Owned: 15.91%
Shares Outstanding: 46.48M
TypeInstitutionsShares
Increased
9
4.01M
New
8
540.87K
Decreased
4
88.61K
Sold Out
16
305.32K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
James Bochnowski
President/Chief Executive Officer/Director
Lisa Conte
Chief Financial Officer/Chief Accounting Officer
Carol Lizak
Executive Vice President
Karen Brunke
Chief Compliance Officer/General Counsel
Jonathan Wolin
Director of Marketing
Chip Whitlow
Secretary
Steven King
Independent Director
Gregory Divis
Independent Director
John Micek
Independent Director
Jonathan Siegel
No Data
About JAGX
Jaguar Health, Inc. is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. The Company's other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

Webull offers kinds of Jaguar Health Inc stock information, including NASDAQ:JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.